Kanjinti (trastuzumab)

pCPA File Number: 21197

Negotiation Status:

Concluded with an LOI

Indication(s):

Early breast cancer, Metastatic breast cancer, Metastatic gastric cancer

Sponsor/Manufacturer:

Amgen Canada Inc.

CDA-AMC Project Number:

Not Applicable

pCPA Engagement Letter Issued:

2020-03-24

Negotiation Process Concluded:

2020-04-16